These observations indicated that the mutational status of DDX3X, TP53 and GNAQ genes might represent a promising marker for therapeutic stratification of patients with NKTCL, which needs to be validated in future large, prospective studies. This evidence concerns the gene TP53 and extranodal nasal NK/T cell lymphoma.